rs459552

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BA1BP1

This summary comes from the ClinGen Evidence Repository: The c.5465T>A variant in APC is a missense variant predicted to cause the substitution of Valine by Asparagine at amino acid position 1822 (p.Val1822Asp). APC is defined by the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel (HCCP VCEP) as a gene for which primarily truncating variants are known to cause disease (BP1). The highest population minor allele frequency in gnomAD v2.1.1 is 0.9598 (23897/24898 alleles) in the African/African American population, which is higher than the ClinGen APC VCEP threshold (>0.1%) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets the criteria to be classified as Benign for FAP based on the ACMG/AMP criteria applied, as specified by the HCCP VCEP: BA1 and BP1 (VCEP specifications version 1; date of approval: 12/12/2022). LINK:https://erepo.genome.network/evrepo/ui/classification/CA010422/MONDO:0021056/089

Frequency

Genomes: 𝑓 0.82 ( 51880 hom., cov: 31)
Exomes 𝑓: 0.78 ( 441782 hom. )

Consequence

APC
NM_000038.6 missense

Scores

1
17

Clinical Significance

Benign reviewed by expert panel B:22O:3

Conservation

PhyloP100: 2.36

Publications

190 publications found
Variant links:
Genes affected
APC (HGNC:583): (APC regulator of WNT signaling pathway) This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Mutations in the APC gene have been found to occur in most colorectal cancers, where disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product. [provided by RefSeq, Jun 2022]
APC Gene-Disease associations (from GenCC):
  • classic or attenuated familial adenomatous polyposis
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • desmoid tumor
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Genomics England PanelApp
  • familial adenomatous polyposis 1
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • gastric adenocarcinoma and proximal polyposis of the stomach
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen, Orphanet
  • sarcoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • APC-related attenuated familial adenomatous polyposis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Turcot syndrome with polyposis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Cenani-Lenz syndactyly syndrome
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP1
For more information check the summary or visit ClinGen Evidence Repository.
BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
APCNM_000038.6 linkc.5465T>A p.Val1822Asp missense_variant Exon 16 of 16 ENST00000257430.9 NP_000029.2 P25054-1Q4LE70

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
APCENST00000257430.9 linkc.5465T>A p.Val1822Asp missense_variant Exon 16 of 16 5 NM_000038.6 ENSP00000257430.4 P25054-1
ENSG00000258864ENST00000520401.1 linkn.228+12087T>A intron_variant Intron 3 of 7 3 ENSP00000454861.1 H3BNH8

Frequencies

GnomAD3 genomes
AF:
0.820
AC:
124670
AN:
152042
Hom.:
51821
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.956
Gnomad AMI
AF:
0.782
Gnomad AMR
AF:
0.812
Gnomad ASJ
AF:
0.761
Gnomad EAS
AF:
0.902
Gnomad SAS
AF:
0.793
Gnomad FIN
AF:
0.669
Gnomad MID
AF:
0.813
Gnomad NFE
AF:
0.761
Gnomad OTH
AF:
0.816
GnomAD2 exomes
AF:
0.795
AC:
199083
AN:
250474
AF XY:
0.789
show subpopulations
Gnomad AFR exome
AF:
0.959
Gnomad AMR exome
AF:
0.827
Gnomad ASJ exome
AF:
0.766
Gnomad EAS exome
AF:
0.903
Gnomad FIN exome
AF:
0.688
Gnomad NFE exome
AF:
0.771
Gnomad OTH exome
AF:
0.792
GnomAD4 exome
AF:
0.777
AC:
1133202
AN:
1459012
Hom.:
441782
Cov.:
53
AF XY:
0.776
AC XY:
563110
AN XY:
725998
show subpopulations
African (AFR)
AF:
0.961
AC:
32111
AN:
33408
American (AMR)
AF:
0.827
AC:
36984
AN:
44696
Ashkenazi Jewish (ASJ)
AF:
0.766
AC:
20005
AN:
26112
East Asian (EAS)
AF:
0.904
AC:
35881
AN:
39672
South Asian (SAS)
AF:
0.779
AC:
67182
AN:
86204
European-Finnish (FIN)
AF:
0.695
AC:
37090
AN:
53394
Middle Eastern (MID)
AF:
0.788
AC:
4543
AN:
5764
European-Non Finnish (NFE)
AF:
0.768
AC:
851815
AN:
1109448
Other (OTH)
AF:
0.789
AC:
47591
AN:
60314
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
14897
29794
44692
59589
74486
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
20486
40972
61458
81944
102430
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.820
AC:
124789
AN:
152160
Hom.:
51880
Cov.:
31
AF XY:
0.816
AC XY:
60692
AN XY:
74374
show subpopulations
African (AFR)
AF:
0.957
AC:
39732
AN:
41534
American (AMR)
AF:
0.812
AC:
12422
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
0.761
AC:
2640
AN:
3468
East Asian (EAS)
AF:
0.902
AC:
4677
AN:
5184
South Asian (SAS)
AF:
0.793
AC:
3823
AN:
4818
European-Finnish (FIN)
AF:
0.669
AC:
7073
AN:
10572
Middle Eastern (MID)
AF:
0.823
AC:
242
AN:
294
European-Non Finnish (NFE)
AF:
0.761
AC:
51747
AN:
67970
Other (OTH)
AF:
0.815
AC:
1720
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1087
2174
3260
4347
5434
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
872
1744
2616
3488
4360
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.779
Hom.:
28582
Bravo
AF:
0.841
TwinsUK
AF:
0.759
AC:
2814
ALSPAC
AF:
0.778
AC:
3000
ESP6500AA
AF:
0.946
AC:
4164
ESP6500EA
AF:
0.765
AC:
6579
ExAC
AF:
0.798
AC:
96838
Asia WGS
AF:
0.856
AC:
2975
AN:
3478
EpiCase
AF:
0.764
EpiControl
AF:
0.775

ClinVar

Significance: Benign
Submissions summary: Benign:22Other:3
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:8Other:1
Mar 01, 2008
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population

- -

-
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 16, 2016
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial adenomatous polyposis 1 Benign:5Other:1
-
GeneReviews
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

- -

Jul 24, 2014
Pathway Genomics
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 15, 2018
SIB Swiss Institute of Bioinformatics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:curation

This variant is interpreted as Benign for Familial adenomatous polyposis 1. The following ACMG Tag(s) were applied: BA1 => Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. -

Feb 26, 2023
ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

The c.5465T>A variant in APC is a missense variant predicted to cause the substitution of Valine by Asparagine at amino acid position 1822 (p.Val1822Asp). APC is defined by the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel (HCCP VCEP) as a gene for which primarily truncating variants are known to cause disease (BP1). The highest population minor allele frequency in gnomAD v2.1.1 is 0.9598 (23897/24898 alleles) in the African/African American population, which is higher than the ClinGen APC VCEP threshold (>0.1%) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets the criteria to be classified as Benign for FAP based on the ACMG/AMP criteria applied, as specified by the HCCP VCEP: BA1 and BP1 (VCEP specifications version 1; date of approval: 12/12/2022). -

not provided Benign:3
Jul 13, 2012
Biesecker Lab/Clinical Genomics Section, National Institutes of Health
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:research

- -

Nov 27, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 24728327, 27347161, 27153395, 9950360, 18343606, 20027139, 21859464, 24599579, 21995949, 20510605, 20149637, 16569251, 16574953, 22703879) -

Hereditary cancer-predisposing syndrome Benign:3
Dec 21, 2021
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Nov 13, 2014
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Mar 27, 2015
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial multiple polyposis syndrome Benign:1
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This p.Val1822Asp variant is not expected to have clinical significance because this residue is not conserved and the variant amino acid (Asp) is present in other mammals such as chimp, macaque, rat and dog as well as some lower evolutionary species, increasing the likelihood that this is a benign variant. In addition, it is not located near a splice junction, and is listed in dbSNP (id:rs459552) with a minor allele frequency of 0.140 in a Caucasian population. The clinical relevance of this variant is still under debate, since some studies showed that it could act as a low-penetrance allele that increases the risk of developing colorectal cancer (CRC) while others consider it as a common polymorphism without clinical consequences (Picelli_2010_20149637). In summary, based on the above information, the p.Val1822Asp variant is predicted to be benign, but we cannot rule out the possibility that this may be a low-penetrance polymorphic allele that increases risk of CRC. -

APC-Associated Polyposis Disorders Benign:1
Mar 06, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Classic or attenuated familial adenomatous polyposis Benign:1
Oct 03, 2024
All of Us Research Program, National Institutes of Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial colorectal cancer Other:1
-
Systems Biology Platform Zhejiang California International NanoSystems Institute
Significance:other
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.046
BayesDel_addAF
Benign
-0.49
T
BayesDel_noAF
Benign
-0.34
CADD
Benign
13
DANN
Benign
0.81
DEOGEN2
Benign
0.27
T;T
Eigen
Benign
-0.65
Eigen_PC
Benign
-0.40
FATHMM_MKL
Benign
0.050
N
LIST_S2
Benign
0.11
.;T
MetaRNN
Benign
6.3e-7
T;T
MetaSVM
Benign
-0.95
T
MutationAssessor
Benign
-0.90
N;N
PhyloP100
2.4
PrimateAI
Uncertain
0.49
T
PROVEAN
Benign
0.59
N;N
REVEL
Benign
0.19
Sift
Benign
0.67
T;T
Sift4G
Benign
0.082
T;T
Polyphen
0.0
B;B
Vest4
0.031
ClinPred
0.0020
T
GERP RS
3.6
Varity_R
0.084
gMVP
0.28
Mutation Taster
=98/2
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs459552; hg19: chr5-112176756; COSMIC: COSV57321643; COSMIC: COSV57321643; API